References
- Dourmishev LA. Inflammatory Myopathies with Cutaneous Involvement: from Diagnosis to Therapy. Folia Med (Plovdiv). 2017; 59(1):7-13.
- Shirani Z, Kucenic MJ, Carroll CL, et al. Pruritus in adult dermatomyositis. Clin Exp Dermatol. 2004; 29(3):273-6.
- Kim HJ. Pruritus in autoimmune connective tissue diseases. Ann Transl Med. 2021; 9(5):441.
- Dourmishev L. Dermatomyositis associated with malignancy. 12 case reports. Adv Exp Med Biol. 1999; 455:193-9.
- Luu X, Leonard S, Joseph KA. Dermatomyositis presenting as a paraneoplastic syndrome with resolution of symptoms following surgical management of underlying breast malignancy. J Surg Case Rep. 2015; 2015(7):rjv075.
- Kamenarska ZG, Hristova MH, Vinkov AI, et al. Monoclonal Antibody Drugs for Systemic Lupus Erythematosus. Folia Med (Plovdiv). 2015; 57(2):89-92.
- Hristova M, Dourmishev L, Kamenarska Z, et al. Role of the promoter polymorphism IL-6-174G/C in dermatomyositis and systemic lupus erythematosus. Biomed Res Int. 2013:315365.
- Hams E, Colmont CS, Dioszeghy V, et al. Oncostatin M receptor-beta signaling limits monocytic cell recruitment in acute inflammation. J Immunol. 2008; 181(3):2174-80.
- Tanaka M, Hara T, Copeland NG et al. Reconstitution of the functional mouse oncostatin M (OSM) receptor: molecular cloning of the mouse OSM receptor beta subunit. Blood. 1999; 93(3):804-15.
- Isozaki O, Tsushima T, Miyakawa M, et al. Oncostatin M: a new potent inhibitor of iodine metabolism inhibits thyroid peroxidase gene expression but not DNA synthesis in porcine thyroid cells in culture. Thyroid. 1997; 7(1):71-7.
- Klausen P, Pedersen L, Jurlander J, et al. Oncostatin M and interleukin 6 inhibit cell cycle progression by prevention of p27kip1 degradation in HepG2 cells. Oncogene. 2000; 19(32):3675-83.
- Bachetti T, Rosamilia F, Bartolucci et al. The OSMR Gene Is Involved in Hirschsprung Associated Enterocolitis Susceptibility through an Altered Downstream Signaling. Int J Mol Sci. 2021; 22(8):3831.
- Kim WM, Kaser A, Blumberg RS. A role for oncostatin M in inflammatory bowel disease. Nat Med. 2017; 23(5):535-536.
- West NR, Hegazy AN, Owens BMJ, et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med. 2017; 23(5):579-589.
- Mozaffarian A, Brewer AW, Trueblood ES, et al. Mechanisms of oncostatin M-induced pulmonary inflammation and fibrosis. J Immunol. 2008; 181(10):7243-53.
- Datsi A, Steinhoff M, Ahmad F, et al. Interleukin-31: The “itchy” cytokine in inflammation and therapy. Allergy. 2021; 76(10):2982-2997.
- Tseng PY, Hoon MA. Oncostatin M can sensitize sensory neurons in inflammatory pruritus. Sci Transl Med. 2021; 13(619):eabe3037.
- Hashimoto T, Nattkemper LA, Kim HS, et al. Itch intensity in prurigo nodularis is closely related to dermal interleukin-31, oncostatin M, IL-31 receptor alpha and oncostatin M receptor beta. Exp Dermatol. 2021; 30(6):804-810.
- Stifano G, Sornasse T, Rice LM, et al. Skin Gene Expression Is Prognostic for the Trajectory of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis. Arthritis Rheumatol. 2018; 70(6):912-919.
- Han L, Yan J, Li T, et al. Multifaceted oncostatin M: novel roles and therapeutic potential of the oncostatin M signaling in rheumatoid arthritis. Front Immunol. 2023; 14:1258765.
- Dillon SR, Sprecher C, Hammond A, et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol. 2004; 5(7):752-60.
- Nemoto O, Furue M, Nakagawa H, et al. The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study. Br J Dermatol. 2016; 174(2):296-304.
- Targoff IN, Miller FW, Medsger TA Jr, et al. Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol. 1997; 9(6):527-35.
- Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012; 64(8):2677-86.
- Heinrich PC, Behrmann I, Haan S, et al. Principles of interleu-kin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003; 374(Pt 1):1-20.
- Lin YZ, Li RN, Lin CH, et al. Association of OSMR gene polymorphisms with rheumatoid arthritis and systemic lupus erythematosus patients. Autoimmunity. 2014; 47(1):23-6.
- Hong IK, Eun YG, Chung DH, et al. Association of the on-costatin m receptor gene polymorphisms with papillary thyroid cancer in the Korean population. Clin Exp Otorhinolaryngol. 2011; 4(4):193-8.
- Deng S, He SY, Zhao P, et al. The role of oncostatin M receptor gene polymorphisms in bladder cancer. World J Surg Oncol. 2019; 17(1):30.
- Dai X, Peng Y, Zhou B, et al. [Association of OSMR gene polymorphisms with dilated cardiomyopathy in a Han Chinese population]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2018; 35(2):210-214.
- Dai X, South AP, Hans-Filho G, et al. Oncostatin M receptor-beta mutations underlie familial primary localized cutaneous amyloidosis. Am J Hum Genet. 2008; 82(1):73-80.
- Tanaka A, Arita K, Lai-Cheong JE, et al. New insight into mechanisms of pruritus from molecular studies on familial primary localized cutaneous amyloidosis. Br J Dermatol. 2009; 161(6):1217-24.
- Sharma M, Samra S, Liu Y, et al. Human germline biallelic loss-of-function OSMR variants cause severe allergic disease. [Preprint]. 2025 Aug 8:2025.08.05.25332527. doi: 10.1101/2025.08.05.25332527.
- Hojman P, Dethlefsen C, Brandt C, et al. Exercise-induced muscle-derived cytokines inhibit mammary cancer cell growth. Am J Physiol Endocrinol Metab. 2011; 301(3):E504-10.
- Lacreusette A, Nguyen JM, Pandolfino MC, et al. Loss of on-costatin M receptor beta in metastatic melanoma cells. Oncogene. 2007; 26(6):881-92.
- Zhong Y, Li J, Zhang Y, et al. The polymorphisms of oncostatin M receptor gene associated with increased risk of lung cancer. Int J Clin Exp Med 2018; 11(11):12421-12428.
- Miles SA, Martínez-Maza O, Rezai A, et al. Oncostatin M as a potent mitogen for AIDS-Kaposi’s sarcoma-derived cells. Science. 1992; 255(5050):1432-4.
- Louthrenoo W, Kasitanon N, Mahanuphab P, et al. Kaposi’s sarcoma in rheumatic diseases. Semin Arthritis Rheum. 2003; 32(5):326-33.